Jedd D. Wolchok
35Patents
4h-index
43Co-inventors
63Inventor score
Filing activity: Nov 27, 2001 → Mar 21, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10736962B2 | Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors | Emerging Cross-Sectional Technologies | 13 | Active |
| US10548930B2 | Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors | Chemistry; Metallurgy | 13 | Active |
| US10639366B2 | Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors | Chemistry; Metallurgy | 8 | Active |
| US10144779B2 | Anti-CTLA-4 antibodies and methods of use thereof | Chemistry; Metallurgy | 5 | Active |
| US10479833B2 | Anti-CTLA-4 antibodies and methods of use thereof | Chemistry; Metallurgy | 4 | Active |
| US10512662B2 | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy | Chemistry; Metallurgy | 4 | Active |
| US10912831B1 | Anti-CTLA-4 antibodies and methods of use thereof | Emerging Cross-Sectional Technologies | 4 | Active |
| US10251922B2 | Newcastle disease viruses and uses thereof | Chemistry; Metallurgy | 4 | Active |
| US10323091B2 | Anti-PD-1 antibodies and methods of use thereof | Chemistry; Metallurgy | 3 | Active |
| US10577426B2 | Anti-GITR antibodies and methods of use thereof | Emerging Cross-Sectional Technologies | 3 | Active |
| US11013802B2 | Anti-CTLA-4 antibodies and methods of use thereof | Emerging Cross-Sectional Technologies | 3 | Active |
| US7556805B2 | Compositions for treatment of melanoma and method of using same | Human Necessities | 2 | Expired |
| US11253560B2 | Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors | Chemistry; Metallurgy | 2 | Active |
| US10800849B2 | Anti-GITR antibodies and methods of use thereof | Emerging Cross-Sectional Technologies | 2 | Active |
| US11285209B2 | Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors | Emerging Cross-Sectional Technologies | 2 | Active |
| US11986503B2 | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy | Chemistry; Metallurgy | 1 | Active |
| US11638755B2 | Anti-CTLA-4 antibodies and methods of use thereof | Emerging Cross-Sectional Technologies | 1 | Active |
| US11541087B2 | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy | Chemistry; Metallurgy | 1 | Active |
| US10765711B2 | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapy | Chemistry; Metallurgy | 1 | Active |
| US11345755B2 | Anti-PD-1 antibodies and methods of use thereof | Chemistry; Metallurgy | 1 | Active |
| US12042534B2 | Newcastle disease viruses and uses thereof | Chemistry; Metallurgy | 1 | Active |
| US12036279B2 | Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors | Emerging Cross-Sectional Technologies | 1 | Active |
| US12246066B2 | Anti-CTLA-4 antibodies and methods of use thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US11267889B2 | Anti-CTLA-4 antibodies and methods of use thereof | Chemistry; Metallurgy | 0 | Active |
| US12397029B2 | Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.